{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:53:22Z","timestamp":1773762802447,"version":"3.50.1"},"reference-count":148,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2004,11,4]],"date-time":"2004-11-04T00:00:00Z","timestamp":1099526400000},"content-version":"vor","delay-in-days":2683,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[1997,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Clozapine, the only commercially available atypical neuroleptic, is approved for the treatment of schizophrenic patients who are unresponsive to or intolerant of typical neuroleptics. It has an unusual pharmacologic profile compared with standard neuroleptics, and it follows that clinical response to this drug is also different. It has shattered the notion that a drug must be capable of inducing or worsening parkinsonism to be a potent antipsychotic. Based on these findings, it is being used increasingly by neurologists for psychiatric and nonpsychiatric problems in patients with movement disorders. The most common use for clozapine among neurologists is in the management of druginduced psychosis in Parkinson's disease (PD). This problem has been a source of increased morbidity and mortality in PD because of a lack of adequate therapeutic intervention. At this time, because of success in numerous open trials, with improvement of &gt;80% of patients, clozapine therapy for psychosis in PD is becoming the standard of care. It also appears to be of value in the management of some motor features of PD, including tremors and dyskinesia and possibly even sensory symptoms such as akathisia and pain. The literature also suggests that clozapine may be of potential benefit in hyperkinetic movement disorders including essential tremor, Huntington's disease, and tardive dyskinesia. We review the current data concerning the use of clozapine in patients with these movement disorders and others.<\/jats:p>","DOI":"10.1002\/mds.870120403","type":"journal-article","created":{"date-parts":[[2005,5,28]],"date-time":"2005-05-28T20:28:13Z","timestamp":1117312093000},"page":"483-496","source":"Crossref","is-referenced-by-count":114,"title":["The emergin role of clozapine in the treatment of movement disorders"],"prefix":"10.1002","volume":"12","author":[{"given":"Stewart A.","family":"Factor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph H.","family":"Friedman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,11,4]]},"reference":[{"key":"e_1_2_1_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1957.02330410029003"},{"key":"e_1_2_1_3_2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0031-6997(25)07428-9","article-title":"The occurrence, distribution and physiological role of catecholamines in the nervous system","volume":"11","author":"Carlsson A","year":"1959","journal-title":"Pharmacol Rev"},{"key":"e_1_2_1_4_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01485901"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM196702162760703"},{"key":"e_1_2_1_6_2","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jama.1971.03190260031009","article-title":"Psychiartric side effects of levodopa in man","volume":"218","author":"Goodwin F","year":"1971","journal-title":"JAMA"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1970.00480270003001"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1991.tb04918.x"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(70)92535-3"},{"key":"e_1_2_1_10_2","first-page":"383","volume-title":"Goodman and Gilman's the pharmacological basis of therapeutics","author":"Baldessarini RJ","year":"1990"},{"key":"e_1_2_1_11_2","first-page":"425","article-title":"Extrapyramidal modification of fine movements: a \u201cconditio sine qua non\u201d of the fundamental therapeutic action of neuroleptic drugs","volume":"20","author":"Haase HY","year":"1961","journal-title":"Rev Can Biol"},{"key":"e_1_2_1_12_2","volume-title":"Synopsis of psychiatry","author":"Kaplan HI","year":"1991"},{"key":"e_1_2_1_13_2","first-page":"41","volume-title":"Drug induced movement disorders","author":"Friedman JH","year":"1992"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199103143241107"},{"key":"e_1_2_1_15_2","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1038\/350610a0","article-title":"Cloning of the gene for a human D4 receptor with high affinity for the antipsychotic clozapine","volume":"350","author":"Van Tol HH","year":"1991","journal-title":"Nature"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3940(93)90370-Z"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198904000-00001"},{"key":"e_1_2_1_18_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820070082019"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820050009001"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(91)90096-9"},{"issue":"17","key":"e_1_2_1_21_2","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1192\/S0007125000296864","article-title":"Clozapine: a hypothesized mechanism for its unique clinical profile","volume":"160","author":"Bunney BS","year":"1992","journal-title":"Br J Psychiatry"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.57.1.119"},{"key":"e_1_2_1_23_2","first-page":"99","article-title":"A case of clozapine\u2010induced neuroleptic malignant syndrome","volume":"52","author":"Miller DD","year":"1991","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198608000-00010"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.161.2.254"},{"key":"e_1_2_1_26_2","first-page":"199","volume-title":"Drug induced movement disorders","author":"Factor SA","year":"1992"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1985.tb01268.x"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442569"},{"key":"e_1_2_1_29_2","first-page":"945","article-title":"Clozapine (Leponex) compared with chlorpromazine: a double\u2010blind evaluation of pharmacological and clinical properties","volume":"16","author":"Ekblom B","year":"1974","journal-title":"Curr Ther Res"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1988.01800330013001"},{"key":"e_1_2_1_31_2","volume-title":"Precis de psychiatrie","author":"Regis E","year":"1906"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneurpsyc.1923.02190300077003"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.38.10.1520"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199108000-00001"},{"key":"e_1_2_1_35_2","first-page":"115","article-title":"Parkinson's disease: drug\u2010induced psychiatric states","volume":"65","author":"Factor SA","year":"1995","journal-title":"Adv Neurol"},{"key":"e_1_2_1_36_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-111-3-218"},{"key":"e_1_2_1_37_2","first-page":"703","article-title":"Treatment of drug\u2010induced psychosis in Parkinson's disease with clozapine","volume":"60","author":"Greene P","year":"1993","journal-title":"Adv Neurol"},{"key":"e_1_2_1_38_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199106000-00013"},{"key":"e_1_2_1_39_2","doi-asserted-by":"crossref","first-page":"447","DOI":"10.3928\/0048-5713-19780901-08","article-title":"Levodopa\u2010induced psychosis","volume":"8","author":"Klawans HL","year":"1978","journal-title":"Psychiatr Ann"},{"key":"e_1_2_1_40_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.135.6.669"},{"key":"e_1_2_1_41_2","first-page":"136","article-title":"Hallucinations in Parkinson's disease: a population study [Abstract]","volume":"14","author":"Tanner CM","year":"1983","journal-title":"Ann Neurol"},{"key":"e_1_2_1_42_2","first-page":"264","article-title":"Visual hallucinations in Parkinson's disease [Abstract]","volume":"34","author":"Sanchez\u2010Ramos JR","year":"1993","journal-title":"Ann Neurol"},{"key":"e_1_2_1_43_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.11.2227"},{"key":"e_1_2_1_44_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1552-4604.1986.tb02969.x"},{"key":"e_1_2_1_45_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.1985.00360050183031"},{"key":"e_1_2_1_46_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198212000-00003"},{"key":"e_1_2_1_47_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198509193131204"},{"key":"e_1_2_1_48_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.30.12.1257"},{"key":"e_1_2_1_49_2","first-page":"33","article-title":"Levodopa\u2010free periods (\u201cdrug holiday\u201d) in the management of parkinsonism","volume":"37","author":"Klawans HL","year":"1983","journal-title":"Adv Neurol"},{"key":"e_1_2_1_50_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.22.5.520"},{"key":"e_1_2_1_51_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-198005000-00013"},{"key":"e_1_2_1_52_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0033291700013763"},{"key":"e_1_2_1_53_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0317167100027141"},{"key":"e_1_2_1_54_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.7.3.304"},{"key":"e_1_2_1_55_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-198710000-00011"},{"key":"e_1_2_1_56_2","first-page":"373","article-title":"Clozapine treatment of psychosis in Parkinson's disease: a report of five consecutive cases","volume":"53","author":"Wolk SI","year":"1992","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00380972"},{"key":"e_1_2_1_58_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.9.1219"},{"key":"e_1_2_1_59_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.1993.tb06743.x"},{"key":"e_1_2_1_60_2","first-page":"204","article-title":"ECT In Parkinson's disease","volume":"8","author":"Friedman JH","year":"1992","journal-title":"Convuls Ther"},{"key":"e_1_2_1_61_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.11.1451"},{"key":"e_1_2_1_62_2","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1176\/ajp.132.10.1084","article-title":"Parkinsonism depression and ECT","volume":"132","author":"Brown GI","year":"1975","journal-title":"Am J Psychiatry"},{"key":"e_1_2_1_63_2","first-page":"321","article-title":"A mechanism for the efficacy of ECT in Parkinson's disease","volume":"4","author":"Fochtmann L","year":"1988","journal-title":"Convuls Ther"},{"key":"e_1_2_1_64_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.146.11.1391"},{"key":"e_1_2_1_65_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870060314"},{"key":"e_1_2_1_66_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF01256635"},{"key":"e_1_2_1_67_2","unstructured":"GranerusAK EkmanR FallPA WolinderJ.ECT in Parkinson's disease\u2014predictors to improvement. Presented at International Symposium on Parkinson's Disease Rome Italy April1994."},{"key":"e_1_2_1_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(95)91001-8"},{"key":"e_1_2_1_69_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.5.832"},{"key":"e_1_2_1_70_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1988.tb03668.x"},{"key":"e_1_2_1_71_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.1.2.190"},{"key":"e_1_2_1_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(89)91816-7"},{"key":"e_1_2_1_73_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050310"},{"key":"e_1_2_1_74_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.40.7.1151"},{"key":"e_1_2_1_75_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.10.1699"},{"key":"e_1_2_1_76_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199106000-00013"},{"issue":"1","key":"e_1_2_1_77_2","first-page":"100","article-title":"Clozapine in Parkinson's disease: three years experience [Abstract]","volume":"7","author":"Linazasaro G","year":"1992","journal-title":"Mov Disord"},{"issue":"1","key":"e_1_2_1_78_2","first-page":"101","article-title":"Analysis of the mechanism of action of clozapine in Parkinson's disease [Abstract]","volume":"7","author":"Gershanik O","year":"1992","journal-title":"Mov Disord"},{"key":"e_1_2_1_79_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.3_Part_1.544"},{"key":"e_1_2_1_80_2","first-page":"277","article-title":"Clozapine for movement disorder patients: a retrospective analysis of 38 patients [Abstract]","volume":"32","author":"Friedman JH","year":"1992","journal-title":"Ann Neurol"},{"key":"e_1_2_1_81_2","doi-asserted-by":"publisher","DOI":"10.1016\/0163-8343(92)90100-O"},{"key":"e_1_2_1_82_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199110000-00019"},{"key":"e_1_2_1_83_2","first-page":"135","article-title":"Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease","volume":"5","author":"Pinter MM","year":"1991","journal-title":"J Neurol Transm"},{"key":"e_1_2_1_84_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.3.432"},{"key":"e_1_2_1_85_2","first-page":"485","article-title":"Other effects of clozapine on Parkinson's disease [Abstract]","volume":"9","author":"Trosch RM","year":"1994","journal-title":"Mov Disord."},{"issue":"4","key":"e_1_2_1_86_2","first-page":"A252","article-title":"Safety and effectiveness of clozapine for parkinsonian patients with psychosis [Abstract]","volume":"45","author":"Brewer MA","year":"1995","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_1_87_2","first-page":"64","article-title":"Low dose clozapine in the treatment of levodopa induced psychosis [Abstract]","volume":"9","author":"Koller WC","year":"1994","journal-title":"Mov Disord"},{"key":"e_1_2_1_88_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.7.4.471"},{"key":"e_1_2_1_89_2","first-page":"A375","article-title":"Clozapine collaborative group. Clozapine use in Parkinson's disease [Abstract]","volume":"46","author":"Trosch RM","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_1_90_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870070205"},{"key":"e_1_2_1_91_2","first-page":"293","volume-title":"Parkinson's disease and movement disorders","author":"Findley LF","year":"1988"},{"key":"e_1_2_1_92_2","first-page":"xx","volume-title":"Advances in parkinsonism","author":"Boshes B","year":"1976"},{"key":"e_1_2_1_93_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1986.tb03279.x"},{"key":"e_1_2_1_94_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870050307"},{"key":"e_1_2_1_95_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02257654"},{"key":"e_1_2_1_96_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1994.tb01677.x"},{"key":"e_1_2_1_97_2","first-page":"A476","article-title":"BCLOZ: a double\u2010blind, crossover trial comparing clozapine with benztropine for treatment in Parkinson's disease [Abstract]","volume":"46","author":"Friedman JH","year":"1996","journal-title":"Neurology"},{"key":"e_1_2_1_98_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1987.00520210023013"},{"key":"e_1_2_1_99_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080317"},{"key":"e_1_2_1_100_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.43.8.1551"},{"key":"e_1_2_1_101_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090406"},{"key":"e_1_2_1_102_2","first-page":"A476","article-title":"Levodopa\u2010induced dyskinesias are improved by low\u2010dose clozapine [Abstract]","volume":"46","author":"Durif F","year":"1996","journal-title":"Neurology"},{"issue":"1","key":"e_1_2_1_103_2","first-page":"102","article-title":"Clozapine treatment of dystonia in Parkinson's disease [Abstract]","volume":"9","author":"Trosch RM","year":"1994","journal-title":"Mov Disord"},{"key":"e_1_2_1_104_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870080209"},{"key":"e_1_2_1_105_2","first-page":"603","article-title":"Clozapine treatment of parkinsonian pain syndromes [Abstract]","volume":"11","author":"Juncos JL","year":"1996","journal-title":"Mov Disord"},{"key":"e_1_2_1_106_2","doi-asserted-by":"publisher","DOI":"10.1176\/jnp.5.2.206"},{"key":"e_1_2_1_107_2","first-page":"556","article-title":"Risperidone versus clozapine in the treatment of psychosis in six patients with Parkinson's disease and other akinetic\u2010rigid syndromes","volume":"56","author":"Rich SA","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_108_2","doi-asserted-by":"publisher","DOI":"10.2190\/PNR2-PW5Y-KF07-H5BE"},{"key":"e_1_2_1_109_2","first-page":"47","article-title":"Clozapine in the treatment of patients with tremor (parkinsonian, essential and neuroleptical\u2010induced) [Abstract]","volume":"7","author":"Simoes F","year":"1992","journal-title":"Mov Disord"},{"issue":"1","key":"e_1_2_1_110_2","first-page":"255","article-title":"Pharmacological tools in the study of essential tremor","volume":"11","author":"Ceravolo R","year":"1996","journal-title":"Mov Disord"},{"key":"e_1_2_1_111_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.136.3.317"},{"key":"e_1_2_1_112_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.5.821"},{"key":"e_1_2_1_113_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.41.1.156"},{"key":"e_1_2_1_114_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.45.5.1023"},{"issue":"1","key":"e_1_2_1_115_2","first-page":"54","article-title":"Clozapine versus placebo in Huntington's disease [Abstract].","volume":"11","author":"van Vugt JPP","year":"1996","journal-title":"Mov Disord"},{"key":"e_1_2_1_116_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002826-199410000-00012"},{"key":"e_1_2_1_117_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.44.5.957"},{"key":"e_1_2_1_118_2","first-page":"121","volume-title":"Drug induced movement disorders","author":"Khot V","year":"1992"},{"key":"e_1_2_1_119_2","first-page":"167","volume-title":"Drug induced movement disorders","author":"Burke RE","year":"1992"},{"key":"e_1_2_1_120_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00442559"},{"key":"e_1_2_1_121_2","first-page":"223","volume-title":"Neuroleptics: neurochemical, behavioral, and clinical perspectives","author":"Jenner P","year":"1983"},{"key":"e_1_2_1_122_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(90)90077-J"},{"issue":"9","key":"e_1_2_1_123_2","first-page":"102","article-title":"Clozapine in tardive dyskinesia: observations from human and animal model studies","volume":"55","author":"Tamminga CA","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_124_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(94)90025-6"},{"key":"e_1_2_1_125_2","first-page":"327","article-title":"Does clozapine cause tardive dyskinesia?","volume":"54","author":"Kane JM","year":"1993","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_126_2","first-page":"47","article-title":"Current views on tardive dyskinesia","volume":"24","author":"Gerlach J","year":"1991","journal-title":"Pharmacopsychiatry"},{"key":"e_1_2_1_127_2","first-page":"700","article-title":"Clinical review of clozapine in treatment in a state psychiatric hospital","volume":"43","author":"Wilson WH","year":"1992","journal-title":"Hosp Community Psychiatry"},{"key":"e_1_2_1_128_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-198410000-00010"},{"key":"e_1_2_1_129_2","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1983.01790030117021"},{"key":"e_1_2_1_130_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.1974.tb09706.x"},{"key":"e_1_2_1_131_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00571412"},{"key":"e_1_2_1_132_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-011-6381-1_39"},{"key":"e_1_2_1_133_2","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-011-6381-1_42"},{"key":"e_1_2_1_134_2","first-page":"263","article-title":"Treatment outcome with clozapine in tardive dyskinesia, neuroleptic sensitivity and treatment resistant psychosis","volume":"48","author":"Small JG","year":"1987","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_135_2","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.158.4.503"},{"key":"e_1_2_1_136_2","doi-asserted-by":"crossref","first-page":"14","DOI":"10.3928\/0279-3695-19930901-07","article-title":"The effect of clozapine on preexisting tardive dyskinesia","volume":"31","author":"Littrell K","year":"1993","journal-title":"J Psychosoc Ment Health Serv"},{"issue":"9","key":"e_1_2_1_137_2","first-page":"107","article-title":"Motor and mental side effects of clozapine","volume":"55","author":"Gerlach J","year":"1994","journal-title":"J Clin Psychiatry"},{"key":"e_1_2_1_138_2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.134.7.785"},{"key":"e_1_2_1_139_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199010000-00029"},{"key":"e_1_2_1_140_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090411"},{"key":"e_1_2_1_141_2","doi-asserted-by":"publisher","DOI":"10.1097\/00005053-199302000-00011"},{"key":"e_1_2_1_142_2","doi-asserted-by":"publisher","DOI":"10.1097\/00004714-199108000-00017"},{"key":"e_1_2_1_143_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870090308"},{"issue":"1","key":"e_1_2_1_144_2","first-page":"220","article-title":"Successful treatment with clozapine in 4 patients with tardive dystonia [Abstract]","volume":"11","author":"Bonuccelli U","year":"1996","journal-title":"Mov Disord"},{"issue":"1","key":"e_1_2_1_145_2","first-page":"230","article-title":"Successful treatment of severe generalized dystonia with clozapine [Abstract]","volume":"11","author":"Valevski A","year":"1996","journal-title":"Movord"},{"issue":"1","key":"e_1_2_1_146_2","first-page":"212","article-title":"Treatment of axial tardive dystonia with clozapine [Abstract]","volume":"11","author":"Borg M","year":"1996","journal-title":"Mov Disord"},{"key":"e_1_2_1_147_2","doi-asserted-by":"publisher","DOI":"10.1016\/0006-3223(95)00218-6"},{"key":"e_1_2_1_148_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.47.4.1085"},{"key":"e_1_2_1_149_2","first-page":"595","article-title":"\u201cSeroquel\u201d (ICI 204, 636) treatment of psychosis in parkinsonism [Abstract]","volume":"11","author":"Evatt ML","year":"1996","journal-title":"Mov Disord"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.870120403","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.870120403","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T14:15:09Z","timestamp":1760969709000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.870120403"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1997,7]]},"references-count":148,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1997,7]]}},"alternative-id":["10.1002\/mds.870120403"],"URL":"https:\/\/doi.org\/10.1002\/mds.870120403","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[1997,7]]}}}